CI-994 Tacedinaline cas 112522-64-2

Tacedinaline is a histone deacetylase (HDAC) inhibitor. Tacedinaline is an anti-cancer agent as HDAC inhibitors block angiogenesis, arrest cell growth, and lead to differentiation and apoptosis in tumor cells. Studies show Tacedinaline to be effective against acute myeloid leukemia in vitro and in vivo when used in combination with conventional anti-cancer agents.

Properties:
Appearance & Physical State: white
Density: 1.322 g/cm3
Boiling Point: 450.6ºC at 760 mmHg
Flash Point: 226.3ºC

Refractive Index: 1.707

Vapor Pressure: 2.6E-08mmHg at 25°C

Related Prodcuts:

Talazoparib; Aleglitazar; Miriplatin; Scriptaid; Ceritinib; CGK733; P005091; PR-619; Gemcitabine; Gemcitabine HCL; Terbinafine hydrochloride; Mitomycin C; Clevudine; Givinostat hydrochloride monohydrate

[1]. Moradei OM, et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6.

[2]. Loprevite M, etal. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res. 2005;15(1):39-48.

[3]. LoRusso PM, et al. Preclinical antitumor activity of CI-994. Invest New Drugs. 1996;14(4):349-56.